{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:06:39Z","timestamp":1790928399360,"version":"4.1.0"},"reference-count":79,"publisher":"Aging and Disease","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging and disease"],"published-print":{"date-parts":[[2021]]},"DOI":"10.14336\/ad.2020.1111","type":"journal-article","created":{"date-parts":[[2021,5,23]],"date-time":"2021-05-23T21:22:46Z","timestamp":1621804966000},"page":"841","source":"Crossref","is-referenced-by-count":37,"title":["Effects of Antihypertensive Drugs on Cognitive Function in Elderly Patients with Hypertension: A Review"],"prefix":"10.14336","volume":"12","author":[{"given":"Wei","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sicong","family":"Si","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5462","reference":[{"key":"key-10.14336\/AD.2020.1111-1","doi-asserted-by":"crossref","unstructured":"Lu J, Lu Y, Wang X, Li X, Linderman GC, Wu C, et al. (2017). Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet, 390:2549-2558.","DOI":"10.1016\/S0140-6736(17)32478-9"},{"key":"key-10.14336\/AD.2020.1111-2","doi-asserted-by":"crossref","unstructured":"Sarki AM, Nduka CU, Stranges S, Kandala NB, Uthman OA (2015). Prevalence of Hypertension in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis. Medicine (Baltimore), 94:e1959.","DOI":"10.1097\/MD.0000000000001959"},{"key":"key-10.14336\/AD.2020.1111-3","doi-asserted-by":"crossref","unstructured":"Burnier M (2019). Treatment of hypertension in the elderly in 2017\/2018 - what's new? Expert Opin Pharmacother, 20:1869-1877.","DOI":"10.1080\/14656566.2019.1638911"},{"key":"key-10.14336\/AD.2020.1111-4","doi-asserted-by":"crossref","unstructured":"Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al. (2020). Screening for Cognitive Impairment in Older Adults: US Preventive Services Task Force Recommendation Statement. JAMA, 323:757-763.","DOI":"10.1001\/jama.2020.0435"},{"key":"key-10.14336\/AD.2020.1111-5","doi-asserted-by":"crossref","unstructured":"Yasar S, Schuchman M, Peters J, Anstey KJ, Carlson MC, Peters R (2016). Relationship Between Antihypertensive Medications and Cognitive Impairment: Part I. Review of Human Studies and Clinical Trials. Curr Hypertens Rep, 18:67.","DOI":"10.1007\/s11906-016-0674-1"},{"key":"key-10.14336\/AD.2020.1111-6","doi-asserted-by":"crossref","unstructured":"Sierra C (2020). Hypertension and the Risk of Dementia. Front Cardiovasc Med, 7:5.","DOI":"10.3389\/fcvm.2020.00005"},{"key":"key-10.14336\/AD.2020.1111-7","doi-asserted-by":"crossref","unstructured":"Turana Y, Tengkawan J, Chia YC, Hoshide S, Shin J, Chen CH, et al. (2019). Hypertension and Dementia: A comprehensive review from the HOPE Asia Network. J Clin Hypertens (Greenwich), 21:1091-1098.","DOI":"10.1111\/jch.13558"},{"key":"key-10.14336\/AD.2020.1111-8","doi-asserted-by":"crossref","unstructured":"Oishi E, Ohara T, Sakata S, Fukuhara M, Hata J, Yoshida D, et al. (2017). Day-to-Day Blood Pressure Variability and Risk of Dementia in a General Japanese Elderly Population: The Hisayama Study. Circulation, 136:516-525.","DOI":"10.1161\/CIRCULATIONAHA.116.025667"},{"key":"key-10.14336\/AD.2020.1111-9","doi-asserted-by":"crossref","unstructured":"Ding J, Davis-Plourde KL, Sedaghat S, Tully PJ, Wang W, Phillips C, et al. (2020). Antihypertensive medications and risk for incident dementia and Alzheimer's disease: a meta-analysis of individual participant data from prospective cohort studies. Lancet Neurol, 19:61-70.","DOI":"10.1016\/S1474-4422(19)30393-X"},{"key":"key-10.14336\/AD.2020.1111-10","unstructured":"Peters R, Yasar S, Anderson CS, Andrews S, Antikainen R, Arima H, et al. (2020). Investigation of antihypertensive class, dementia, and cognitive decline: A meta-analysis. Neurology, 94:e267-e281."},{"key":"key-10.14336\/AD.2020.1111-11","unstructured":"Hua Q, Fan L, Li J (2019). 2019 Chinese guideline for the management of hypertension in the elderly. J Geriatr Cardiol, 16:67-99."},{"key":"key-10.14336\/AD.2020.1111-12","doi-asserted-by":"crossref","unstructured":"Benetos A, Petrovic M, Strandberg T (2019). Hypertension Management in Older and Frail Older Patients. Circ Res, 124:1045-1060.","DOI":"10.1161\/CIRCRESAHA.118.313236"},{"key":"key-10.14336\/AD.2020.1111-13","doi-asserted-by":"crossref","unstructured":"Wang ZT, Xu W, Wang HF, Tan L, Tan CC, Li JQ, et al. (2018). Blood Pressure and the Risk of Dementia: A Dose-Response Meta-Analysis of Prospective Studies. Curr Neurovasc Res, 15:345-358.","DOI":"10.2174\/1567202616666181128114523"},{"key":"key-10.14336\/AD.2020.1111-14","doi-asserted-by":"crossref","unstructured":"Razay G, Williams J, King E, Smith AD, Wilcock G (2009). Blood pressure, dementia and Alzheimer's disease: the OPTIMA longitudinal study. Dement Geriatr Cogn Disord, 28:70-74.","DOI":"10.1159\/000230877"},{"key":"key-10.14336\/AD.2020.1111-15","doi-asserted-by":"crossref","unstructured":"Streit S, Poortvliet RKE, Gussekloo J (2018). Lower blood pressure during antihypertensive treatment is associated with higher all-cause mortality and accelerated cognitive decline in the oldest-old. Data from the Leiden 85-plus Study. Age Ageing, 47:545-550.","DOI":"10.1093\/ageing\/afy072"},{"key":"key-10.14336\/AD.2020.1111-16","doi-asserted-by":"crossref","unstructured":"Peters R, Collerton J, Granic A, Davies K, Kirkwood T, Jagger C (2015). Antihypertensive drug use and risk of cognitive decline in the very old: an observational study - the Newcastle 85+ Study. J Hypertens, 33:2156-2164.","DOI":"10.1097\/HJH.0000000000000653"},{"key":"key-10.14336\/AD.2020.1111-17","doi-asserted-by":"crossref","unstructured":"Williamson JD, Launer LJ, Bryan RN, Coker LH, Lazar RM, Gerstein HC, et al. (2014). Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Intern Med, 174:324-333.","DOI":"10.1001\/jamainternmed.2013.13656"},{"key":"key-10.14336\/AD.2020.1111-18","unstructured":"Williamson JD, Pajewski NM, Auchus AP, Bryan RN, Chelune G, Cheung AK, et al. (2019). Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA, 321:553-561."},{"key":"key-10.14336\/AD.2020.1111-19","doi-asserted-by":"crossref","unstructured":"Pajewski NM, Berlowitz DR, Bress AP, Callahan KE, Cheung AK, Fine LJ, et al. (2020). Intensive vs Standard Blood Pressure Control in Adults 80 Years or Older: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial. J Am Geriatr Soc, 68:496-504.","DOI":"10.1111\/jgs.16272"},{"key":"key-10.14336\/AD.2020.1111-20","doi-asserted-by":"crossref","unstructured":"Ma Y, Wolters FJ, Chibnik LB, Licher S, Ikram MA, Hofman A, et al. (2019). Variation in blood pressure and long-term risk of dementia: A population-based cohort study. PLoS Med, 16:e1002933.","DOI":"10.1371\/journal.pmed.1002933"},{"key":"key-10.14336\/AD.2020.1111-21","unstructured":"Tully PJ, Yano Y, Launer LJ, Kario K, Nagai M, Mooijaart SP, et al. (2020). Association Between Blood Pressure Variability and Cerebral Small-Vessel Disease: A Systematic Review and Meta-Analysis. J Am Heart Assoc, 9:e013841."},{"key":"key-10.14336\/AD.2020.1111-22","doi-asserted-by":"crossref","unstructured":"Bos D, Wolters FJ, Darweesh SKL, Vernooij MW, de Wolf F, Ikram MA, et al. (2018). Cerebral small vessel disease and the risk of dementia: A systematic review and meta-analysis of population-based evidence. Alzheimers Dement, 14:1482-1492.","DOI":"10.1016\/j.jalz.2018.04.007"},{"key":"key-10.14336\/AD.2020.1111-23","doi-asserted-by":"crossref","unstructured":"Xin W, Lin Z, Mi S (2014). Orthostatic hypotension and mortality risk: a meta-analysis of cohort studies. Heart, 100:406-413.","DOI":"10.1136\/heartjnl-2013-304121"},{"key":"key-10.14336\/AD.2020.1111-24","doi-asserted-by":"crossref","unstructured":"Xin W, Mi S, Lin Z, Wang H, Wei W (2016). Orthostatic hypotension and the risk of incidental cardiovascular diseases: A meta-analysis of prospective cohort studies. Prev Med, 85:90-97.","DOI":"10.1016\/j.ypmed.2016.01.007"},{"key":"key-10.14336\/AD.2020.1111-25","doi-asserted-by":"crossref","unstructured":"Colloby SJ, Vasudev A, O'Brien JT, Firbank MJ, Parry SW, Thomas AJ (2011). Relationship of orthostatic blood pressure to white matter hyperintensities and subcortical volumes in late-life depression. Br J Psychiatry, 199:404-410.","DOI":"10.1192\/bjp.bp.110.090423"},{"key":"key-10.14336\/AD.2020.1111-26","doi-asserted-by":"crossref","unstructured":"Brodziak A, Wolinska A, Kolat E, Rozyk-Myrta A (2015). Guidelines for prevention and treatment of cognitive impairment in the elderly. Med Sci Monit, 21:585-597.","DOI":"10.12659\/MSM.892542"},{"key":"key-10.14336\/AD.2020.1111-27","doi-asserted-by":"crossref","unstructured":"Peters R, Anstey KJ, Booth A, Beckett N, Warwick J, Antikainen R, et al. (2018). Orthostatic hypotension and symptomatic subclinical orthostatic hypotension increase risk of cognitive impairment: an integrated evidence review and analysis of a large older adult hypertensive cohort. Eur Heart J, 39:3135-3143.","DOI":"10.1093\/eurheartj\/ehy418"},{"key":"key-10.14336\/AD.2020.1111-28","doi-asserted-by":"crossref","unstructured":"Iseli R, Nguyen VTV, Sharmin S, Reijnierse EM, Lim WK, Maier AB (2019). Orthostatic hypotension and cognition in older adults: A systematic review and meta-analysis. Exp Gerontol, 120:40-49.","DOI":"10.1016\/j.exger.2019.02.017"},{"key":"key-10.14336\/AD.2020.1111-29","doi-asserted-by":"crossref","unstructured":"Gebre AK, Altaye BM, Atey TM, Tuem KB, Berhe DF (2018). Targeting Renin-Angiotensin System Against Alzheimer's Disease. Front Pharmacol, 9:440.","DOI":"10.3389\/fphar.2018.00440"},{"key":"key-10.14336\/AD.2020.1111-30","doi-asserted-by":"crossref","unstructured":"Duchemin S, Belanger E, Wu R, Ferland G, Girouard H (2013). Chronic perfusion of angiotensin II causes cognitive dysfunctions and anxiety in mice. Physiol Behav, 109:63-68.","DOI":"10.1016\/j.physbeh.2012.10.005"},{"key":"key-10.14336\/AD.2020.1111-31","doi-asserted-by":"crossref","unstructured":"Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, et al. (2003). Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med, 163:1069-1075.","DOI":"10.1001\/archinte.163.9.1069"},{"key":"key-10.14336\/AD.2020.1111-32","doi-asserted-by":"crossref","unstructured":"Dufouil C, Chalmers J, Coskun O, Besancon V, Bousser MG, Guillon P, et al. (2005). Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation, 112:1644-1650.","DOI":"10.1161\/CIRCULATIONAHA.104.501163"},{"key":"key-10.14336\/AD.2020.1111-33","doi-asserted-by":"crossref","unstructured":"Yamada K, Horita T, Takayama M, Takahashi S, Takaba K, Nagata Y, et al. (2011). Effect of a centrally active angiotensin converting enzyme inhibitor, perindopril, on cognitive performance in chronic cerebral hypo-perfusion rats. Brain Res, 1421:110-120.","DOI":"10.1016\/j.brainres.2011.09.016"},{"key":"key-10.14336\/AD.2020.1111-34","doi-asserted-by":"crossref","unstructured":"Ohrui T, Tomita N, Sato-Nakagawa T, Matsui T, Maruyama M, Niwa K, et al. (2004). Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology, 63:1324-1325.","DOI":"10.1212\/01.WNL.0000140705.23869.E9"},{"key":"key-10.14336\/AD.2020.1111-35","doi-asserted-by":"crossref","unstructured":"Ongali B, Nicolakakis N, Tong XK, Aboulkassim T, Imboden H, Hamel E (2016). Enalapril Alone or Co-Administered with Losartan Rescues Cerebrovascular Dysfunction, but not Mnemonic Deficits or Amyloidosis in a Mouse Model of Alzheimer's Disease. J Alzheimers Dis, 51:1183-1195.","DOI":"10.3233\/JAD-150868"},{"key":"key-10.14336\/AD.2020.1111-36","doi-asserted-by":"crossref","unstructured":"Sink KM, Leng X, Williamson J, Kritchevsky SB, Yaffe K, Kuller L, et al. (2009). Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. Arch Intern Med, 169:1195-1202.","DOI":"10.1001\/archinternmed.2009.175"},{"key":"key-10.14336\/AD.2020.1111-37","doi-asserted-by":"crossref","unstructured":"Qiu WQ, Mwamburi M, Besser LM, Zhu H, Li H, Wallack M, et al. (2013). Angiotensin converting enzyme inhibitors and the reduced risk of Alzheimer's disease in the absence of apolipoprotein E4 allele. J Alzheimers Dis, 37:421-428.","DOI":"10.3233\/JAD-130716"},{"key":"key-10.14336\/AD.2020.1111-38","doi-asserted-by":"crossref","unstructured":"Guo Z, Fratiglioni L, Zhu L, Fastbom J, Winblad B, Viitanen M (1999). Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. Arch Neurol, 56:991-996.","DOI":"10.1001\/archneur.56.8.991"},{"key":"key-10.14336\/AD.2020.1111-39","doi-asserted-by":"crossref","unstructured":"Chuang YF, Breitner JCS, Chiu YL, Khachaturian A, Hayden K, Corcoran C, et al. (2014). Use of diuretics is associated with reduced risk of Alzheimer's disease: the Cache County Study. Neurobiol Aging, 35:2429-2435.","DOI":"10.1016\/j.neurobiolaging.2014.05.002"},{"key":"key-10.14336\/AD.2020.1111-40","doi-asserted-by":"crossref","unstructured":"Mielke MM, Zandi PP, Blennow K, Gustafson D, Sjogren M, Rosengren L, et al. (2006). Low serum potassium in mid life associated with decreased cerebrospinal fluid Abeta42 in late life. Alzheimer Dis Assoc Disord, 20:30-36.","DOI":"10.1097\/01.wad.0000201848.67954.7d"},{"key":"key-10.14336\/AD.2020.1111-41","doi-asserted-by":"crossref","unstructured":"Zhao W, Xu S, Peng Y, Ji X, Cao D, Li J, et al. (2013). Potassium 2-(1-hydroxypentyl)-benzoate improves learning and memory deficits in chronic cerebral hypoperfused rats. Neurosci Lett, 541:155-160.","DOI":"10.1016\/j.neulet.2013.01.053"},{"key":"key-10.14336\/AD.2020.1111-42","doi-asserted-by":"crossref","unstructured":"DeLoach T, Beall J (2018). Diuretics: A possible keystone in upholding cognitive health. Ment Health Clin, 8:33-40.","DOI":"10.9740\/mhc.2018.01.033"},{"key":"key-10.14336\/AD.2020.1111-43","doi-asserted-by":"crossref","unstructured":"Yasar S, Lin FM, Fried LP, Kawas CH, Sink KM, DeKosky ST, et al. (2012). Diuretic use is associated with better learning and memory in older adults in the Ginkgo Evaluation of Memory Study. Alzheimers Dement, 8:188-195.","DOI":"10.1016\/j.jalz.2011.03.010"},{"key":"key-10.14336\/AD.2020.1111-44","doi-asserted-by":"crossref","unstructured":"Maranta F, Spoladore R, Fragasso G (2017). Pathophysiological Mechanisms and Correlates of Therapeutic Pharmacological Interventions in Essential Arterial Hypertension. Adv Exp Med Biol, 956:37-59.","DOI":"10.1007\/5584_2016_169"},{"key":"key-10.14336\/AD.2020.1111-45","doi-asserted-by":"crossref","unstructured":"Kehoe PG (2018). The Coming of Age of the Angiotensin Hypothesis in Alzheimer's Disease: Progress Toward Disease Prevention and Treatment? J Alzheimers Dis, 62:1443-1466.","DOI":"10.3233\/JAD-171119"},{"key":"key-10.14336\/AD.2020.1111-46","doi-asserted-by":"crossref","unstructured":"Skoog I, Lithell H, Hansson L, Elmfeldt D, Hofman A, Olofsson B, et al. (2005). Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). Am J Hypertens, 18:1052-1059.","DOI":"10.1016\/j.amjhyper.2005.02.013"},{"key":"key-10.14336\/AD.2020.1111-47","doi-asserted-by":"crossref","unstructured":"Hanon O, Berrou JP, Negre-Pages L, Goch JH, Nadhazi Z, Petrella R, et al. (2008). Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study. J Hypertens, 26:1642-1650.","DOI":"10.1097\/HJH.0b013e328301a280"},{"key":"key-10.14336\/AD.2020.1111-48","doi-asserted-by":"crossref","unstructured":"Radaideh GA, Choueiry P, Ismail A, Eid E, Berrou JP, Sedefdjian A, et al. (2011). Eprosartan-based hypertension therapy, systolic arterial blood pressure and cognitive function: analysis of Middle East data from the OSCAR study. Vasc Health Risk Manag, 7:491-495.","DOI":"10.2147\/VHRM.S19699"},{"key":"key-10.14336\/AD.2020.1111-49","doi-asserted-by":"crossref","unstructured":"Hajjar I, Hart M, Chen YL, Mack W, Novak V, H CC, et al. (2013). Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. J Am Geriatr Soc, 61:194-201.","DOI":"10.1111\/jgs.12100"},{"key":"key-10.14336\/AD.2020.1111-50","doi-asserted-by":"crossref","unstructured":"Danielyan L, Klein R, Hanson LR, Buadze M, Schwab M, Gleiter CH, et al. (2010). Protective effects of intranasal losartan in the APP\/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res, 13:195-201.","DOI":"10.1089\/rej.2009.0944"},{"key":"key-10.14336\/AD.2020.1111-51","doi-asserted-by":"crossref","unstructured":"Ahmed HA, Ishrat T, Pillai B, Fouda AY, Sayed MA, Eldahshan W, et al. (2018). RAS modulation prevents progressive cognitive impairment after experimental stroke: a randomized, blinded preclinical trial. J Neuroinflammation, 15:229.","DOI":"10.1186\/s12974-018-1262-x"},{"key":"key-10.14336\/AD.2020.1111-52","doi-asserted-by":"crossref","unstructured":"Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, et al. (2010). Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ, 340:b5465.","DOI":"10.1136\/bmj.b5465"},{"key":"key-10.14336\/AD.2020.1111-53","unstructured":"Li W, Zhang JW, Lu F, Ma MM, Wang JQ, Suo AQ, et al. (2012). [Effects of telmisartan on the level of Abeta1-42, interleukin-1beta, tumor necrosis factor alpha and cognition in hypertensive patients with Alzheimer's disease]. Zhonghua Yi Xue Za Zhi, 92:2743-2746."},{"key":"key-10.14336\/AD.2020.1111-54","doi-asserted-by":"crossref","unstructured":"Levi Marpillat N, Macquin-Mavier I, Tropeano AI, Bachoud-Levi AC, Maison P (2013). Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens, 31:1073-1082.","DOI":"10.1097\/HJH.0b013e3283603f53"},{"key":"key-10.14336\/AD.2020.1111-55","doi-asserted-by":"crossref","unstructured":"Ye R, Hu Y, Yao A, Yang Y, Shi Y, Jiang Y, et al. (2015). Impact of renin-angiotensin system-targeting antihypertensive drugs on treatment of Alzheimer's disease: a meta-analysis. Int J Clin Pract, 69:674-681.","DOI":"10.1111\/ijcp.12626"},{"key":"key-10.14336\/AD.2020.1111-56","doi-asserted-by":"crossref","unstructured":"Nakagawa T, Hasegawa Y, Uekawa K, Senju S, Nakagata N, Matsui K, et al. (2017). Transient Mild Cerebral Ischemia Significantly Deteriorated Cognitive Impairment in a Mouse Model of Alzheimer's Disease via Angiotensin AT1 Receptor. Am J Hypertens, 30:141-150.","DOI":"10.1093\/ajh\/hpw099"},{"key":"key-10.14336\/AD.2020.1111-57","doi-asserted-by":"crossref","unstructured":"Wincewicz D, Juchniewicz A, Waszkiewicz N, Braszko JJ (2016). Angiotensin II type 1 receptor blockade by telmisartan prevents stress-induced impairment of memory via HPA axis deactivation and up-regulation of brain-derived neurotrophic factor gene expression. Pharmacol Biochem Behav, 148:108-118.","DOI":"10.1016\/j.pbb.2016.06.010"},{"key":"key-10.14336\/AD.2020.1111-58","doi-asserted-by":"crossref","unstructured":"Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, et al. (1998). Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet, 352:1347-1351.","DOI":"10.1016\/S0140-6736(98)03086-4"},{"key":"key-10.14336\/AD.2020.1111-59","doi-asserted-by":"crossref","unstructured":"Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, et al. (2002). The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med, 162:2046-2052.","DOI":"10.1001\/archinte.162.18.2046"},{"key":"key-10.14336\/AD.2020.1111-60","doi-asserted-by":"crossref","unstructured":"Hwang D, Kim S, Choi H, Oh IH, Kim BS, Choi HR, et al. (2016). Calcium-Channel Blockers and Dementia Risk in Older Adults- National Health Insurance Service - Senior Cohort (2002-2013). Circ J, 80:2336-2342.","DOI":"10.1253\/circj.CJ-16-0692"},{"key":"key-10.14336\/AD.2020.1111-61","doi-asserted-by":"crossref","unstructured":"Hanon O, Pequignot R, Seux ML, Lenoir H, Bune A, Rigaud AS, et al. (2006). Relationship between antihypertensive drug therapy and cognitive function in elderly hypertensive patients with memory complaints. J Hypertens, 24:2101-2107.","DOI":"10.1097\/01.hjh.0000244961.69985.05"},{"key":"key-10.14336\/AD.2020.1111-62","doi-asserted-by":"crossref","unstructured":"Shah K, Qureshi SU, Johnson M, Parikh N, Schulz PE, Kunik ME (2009). Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am J Geriatr Pharmacother, 7:250-261.","DOI":"10.1016\/j.amjopharm.2009.11.001"},{"key":"key-10.14336\/AD.2020.1111-63","doi-asserted-by":"crossref","unstructured":"Peters R, Booth A, Peters J (2014). A systematic review of calcium channel blocker use and cognitive decline\/dementia in the elderly. J Hypertens, 32:1945-1957; discussion 1957-1948.","DOI":"10.1097\/HJH.0000000000000273"},{"key":"key-10.14336\/AD.2020.1111-64","doi-asserted-by":"crossref","unstructured":"Angeli F, Verdecchia P, Reboldi GP, Gattobigio R, Bentivoglio M, Staessen JA, et al. (2004). Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. Am J Hypertens, 17:817-822.","DOI":"10.1016\/S0895-7061(04)00863-5"},{"key":"key-10.14336\/AD.2020.1111-65","doi-asserted-by":"crossref","unstructured":"Yu JT, Chang RC, Tan L (2009). Calcium dysregulation in Alzheimer's disease: from mechanisms to therapeutic opportunities. Prog Neurobiol, 89:240-255.","DOI":"10.1016\/j.pneurobio.2009.07.009"},{"key":"key-10.14336\/AD.2020.1111-66","doi-asserted-by":"crossref","unstructured":"Sze KH, Sim TC, Wong E, Cheng S, Woo J (1998). Effect of nimodipine on memory after cerebral infarction. Acta Neurol Scand, 97:386-392.","DOI":"10.1111\/j.1600-0404.1998.tb05971.x"},{"key":"key-10.14336\/AD.2020.1111-67","unstructured":"Lopez-Arrieta JM, Birks J (2002). Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev:CD000147."},{"key":"key-10.14336\/AD.2020.1111-68","doi-asserted-by":"crossref","unstructured":"Pantoni L, del Ser T, Soglian AG, Amigoni S, Spadari G, Binelli D, et al. (2005). Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial. Stroke, 36:619-624.","DOI":"10.1161\/01.STR.0000155686.73908.3e"},{"key":"key-10.14336\/AD.2020.1111-69","doi-asserted-by":"crossref","unstructured":"Schiffrin EL (2003). Effect of antihypertensive treatment on small artery remodeling in hypertension. Can J Physiol Pharmacol, 81:168-176.","DOI":"10.1139\/y02-158"},{"key":"key-10.14336\/AD.2020.1111-70","doi-asserted-by":"crossref","unstructured":"Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. (2006). Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation, 113:1213-1225.","DOI":"10.1161\/CIRCULATIONAHA.105.595496"},{"key":"key-10.14336\/AD.2020.1111-71","doi-asserted-by":"crossref","unstructured":"Rizzoni D, Muiesan ML, Porteri E, De Ciuceis C, Boari GE, Salvetti M, et al.(2009). Vascular remodeling, macro- and microvessels: therapeutic implications. Blood Press, 18:242-246.","DOI":"10.1080\/08037050903254923"},{"key":"key-10.14336\/AD.2020.1111-72","doi-asserted-by":"crossref","unstructured":"Peters R, Beckett N (2009). Hypertension, dementia, and antihypertensive treatment: implications for the very elderly. Curr Hypertens Rep, 11:277-282.","DOI":"10.1007\/s11906-009-0047-0"},{"key":"key-10.14336\/AD.2020.1111-73","doi-asserted-by":"crossref","unstructured":"Arrieta-Cruz I, Wang J, Pavlides C, Pasinetti GM (2010). Carvedilol reestablishes long-term potentiation in a mouse model of Alzheimer's disease. J Alzheimers Dis, 21:649-654.","DOI":"10.3233\/JAD-2010-100225"},{"key":"key-10.14336\/AD.2020.1111-74","doi-asserted-by":"crossref","unstructured":"Wang J, Ono K, Dickstein DL, Arrieta-Cruz I, Zhao W, Qian X, et al. (2011). Carvedilol as a potential novel agent for the treatment of Alzheimer's disease. Neurobiol Aging, 32:2321 e2321-2312.","DOI":"10.1016\/j.neurobiolaging.2010.05.004"},{"key":"key-10.14336\/AD.2020.1111-75","doi-asserted-by":"crossref","unstructured":"Luong K, Nguyen LT (2013). The role of Beta-adrenergic receptor blockers in Alzheimer's disease: potential genetic and cellular signaling mechanisms. Am J Alzheimers Dis Other Demen, 28:427-439.","DOI":"10.1177\/1533317513488924"},{"key":"key-10.14336\/AD.2020.1111-76","doi-asserted-by":"crossref","unstructured":"Yasar S, Xia J, Yao W, Furberg CD, Xue QL, Mercado CI, et al. (2013). Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Neurology, 81:896-903.","DOI":"10.1212\/WNL.0b013e3182a35228"},{"key":"key-10.14336\/AD.2020.1111-77","doi-asserted-by":"crossref","unstructured":"Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, Norton MC, et al. (2006). Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol, 63:686-692.","DOI":"10.1001\/archneur.63.5.noc60013"},{"key":"key-10.14336\/AD.2020.1111-78","doi-asserted-by":"crossref","unstructured":"Gelber RP, Ross GW, Petrovitch H, Masaki KH, Launer LJ, White LR (2013). Antihypertensive medication use and risk of cognitive impairment: the Honolulu-Asia Aging Study. Neurology, 81:888-895.","DOI":"10.1212\/WNL.0b013e3182a351d4"},{"key":"key-10.14336\/AD.2020.1111-79","doi-asserted-by":"crossref","unstructured":"Prince MJ, Bird AS, Blizard RA, Mann AH (1996). Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. BMJ, 312:801-805.","DOI":"10.1136\/bmj.312.7034.801"}],"container-title":["Aging and disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.aginganddisease.org\/fileup\/2152-5250\/PDF\/ad-0-0-0-2011111258-1.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T01:40:08Z","timestamp":1627522808000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.aginganddisease.org\/EN\/10.14336\/AD.2020.1111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.14336\/ad.2020.1111","relation":{},"ISSN":["2152-5250"],"issn-type":[{"value":"2152-5250","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}